152 related articles for article (PubMed ID: 29078212)
1. [Current Status of Targeted Treatment in Breast Cancer].
Seiffert K; Schmalfeldt B; Müller V
Dtsch Med Wochenschr; 2017 Nov; 142(22):1669-1675. PubMed ID: 29078212
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.
Turner NC; Neven P; Loibl S; Andre F
Lancet; 2017 Jun; 389(10087):2403-2414. PubMed ID: 27939057
[TBL] [Abstract][Full Text] [Related]
3. [Systemic Treatment of Early and Metastatic Breast Cancer].
Fehm T; Müller V
Dtsch Med Wochenschr; 2018 Dec; 143(24):1751-1754. PubMed ID: 30508853
[TBL] [Abstract][Full Text] [Related]
4. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.
Gu G; Dustin D; Fuqua SA
Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943
[TBL] [Abstract][Full Text] [Related]
6. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
7. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
8. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
9. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
11. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
13. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
14. [Combination Therapy of Molecular-Targeted Drugs for Breast Cancer -- Their Potential in the Future].
Okano M; Ohtake T; Saji S
Gan To Kagaku Ryoho; 2016 Apr; 43(4):398-403. PubMed ID: 27220784
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibition in early and metastatic breast cancer: A review.
de Groot AF; Kuijpers CJ; Kroep JR
Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
[TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy: is the first generation of targeted drugs the last?
Pritchard KI
J Intern Med; 2013 Aug; 274(2):144-52. PubMed ID: 23844917
[TBL] [Abstract][Full Text] [Related]
18. Targeting the HER2 receptor in metastatic breast cancer.
Orphanos G; Kountourakis P
Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
[TBL] [Abstract][Full Text] [Related]
20. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
